Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 3 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.

Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA Filed
Marketed
Niraparib (ZL-2306)
Ovarian Cancer (2nd line maintenance) */PK Study
China
Hong Kong
Ovarian Cancer (1st line maintenance)
Small Cell Lung Cancer
IO Combo in Gastric Cancer[2]
IO Combo in Ovarian Cancer[2]
IO Combo in NSCLC[2]
Other [1]
Tumor Treating Fields (Optune®)
Glioblastoma (GBM) *
Hong Kong
Mesothelioma
NSCLC
Brain Metastases
Pancreatic Cancer
Ovarian Cancer
Gastric Cancer
Margetuximab
HER2+ Breast Cancer
HER2+ Gastric Cancer [2]
MGD-013
Ovarian[2]
Gastric[1]
TNBC
NSCLC
HCC
Other[2]
FPA144 (Bemarituzumab)
Gastric Cancer / GEJ
Brivanib (ZL-2301)
Hepatocellular Carcinoma (HCC) [2]
Omadacycline (ZL-2401)
No data!
ETX2514
No data!
Infectious Disease and Autoimmune
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA Filed
Marketed
Niraparib (ZL-2306)
No data!
Tumor Treating Fields (Optune®)
No data!
Margetuximab
No data!
MGD-013
No data!
FPA144 (Bemarituzumab)
No data!
Brivanib (ZL-2301)
No data!
Omadacycline (ZL-2401)
Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
Community-Acquired Bacterial Pneumonia (CABP) *
ETX2514
A.Baumanii Bacterial Infections

Note: [1] Combo and mono therapy  [2] Combo therapy